Biotech News
Xenon Reports Q1 2026 Financial Results and Provides Business Update
investor.xenon-pharma.com2026-05-07 20:02 EST
Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and depression indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Phase